{
  "docId": "019de073-ce1e-74cc-9870-b1827d8467a5",
  "docSlug": "ce894072ac0bdbdb4be0c6e520599e56",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 31 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 31,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 35,
  "notes": "Clinical trial data presentation for ENA 2022.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ce1e-74cc-9870-b1827d8467a5/16",
  "deckHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5",
  "deckJsonHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5.json",
  "deckAnchorHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. CNS, central nervous system, NE, not evaluable; ORR, objective response rate; PD, progressive disease, PR, partial response, RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; SD, stable disease, TKI, tyrosine kinase inhibitor. a Includes 2 ongoing partial responses pending confirmation. b Includes 1 ongoing partial response pending confirmation. c Patient discontinued treatment due to clinical progression without post-baseline radiographic assessment. d These prior ROS1 TKIs were discontinued due to progressive disease in 17/18 patients.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1146d69e-f821-4353-8b86-fab7a716f2fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.85,
        "x": 0.07,
        "y": 0.288
      },
      "kind": "table",
      "text": "Table showing patient counts (n) and ORR percentages across five patient cohorts (All, ROS1 G2032R, CNS Mets, Prior TKI/Chemo, Prior Lorlatinib/Repotrectinib) and response categories (PR, SD, PD, NE).",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b840087-baef-44f4-8c50-14bb1b1ab020",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.14
      },
      "kind": "title",
      "text": "Preliminary Efficacy | NVL-520 Induced Tumor Response Across Heavily Pretreated Patient Populations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36d9a7f5-c993-447f-90c2-d41e28a5d53c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b01545f0-fd92-41f4-970e-28b5cb49def6",
      "evidence": "Slides 6-16 discuss the limitations of current treatments and the potential benefits of Nuvalent's therapies.",
      "position": 0,
      "objective": "What is the cost of not developing effective treatments for cancer patients with specific genetic mutations?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}